In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for ...on August 21, 2021 at 6:27 am
Data shows that the administration of Rhenium-186 NanoLiposome (186RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than ...
- Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Canceron August 21, 2021 at 6:27 am
AUSTIN, Texas, Aug. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics ... 39 patients across three different cohorts based on their specific disease diagnosis. The primary endpoint of the study ...
- Do Marker Therapeutics Inc. (MRKR) beta value of 1.25 signposts another twist?on August 20, 2021 at 3:52 pm
Marker Therapeutics Inc. (MRKR) is priced at $1.68 after the most recent trading session. At the very opening of the session, the stock price was $1.74 and reached a high price of $1.80, prior to ...
- COVID: UK regulator approves first coronavirus-specific drug for useon August 20, 2021 at 4:48 am
Mr Javid said: "This is fantastic news from the independent medicines regulator and means the UK has approved its first therapeutic designed specifically for COVID-19. "This treatment will be a ...
- Combatting SARS-CoV-2: Potential Therapeutic Candidates Against COVID-19on August 19, 2021 at 11:29 pm
Severe cases of pneumonia of unknown aetiology from Wuhan, in the Hubei province of China, were reported to the World Health Organization’s (WHO) China Country Office on 31st December ...
- Here is why Marker Therapeutics Inc. (MRKR) stock turnaround in the after-hours on Thursday?on August 19, 2021 at 9:18 pm
Marker Therapeutics Inc. (MRKR) shares surged 23.81% in after-hours on Thursday & closed at $2.08. We have covered its last two months news.
- Dermata Therapeutics IPO (DRMA) Stockon August 19, 2021 at 6:24 pm
As society gradually eyes a return to normal, biotech firm Dermata Therapeutics aims to restore confidence among the millions suffering from skin conditions.
- Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texason August 19, 2021 at 1:06 pm
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological ...
- Do Fate Therapeutics Inc. (FATE) beta value of 1.65 signposts another twist?on August 19, 2021 at 9:31 am
Fate Therapeutics Inc. (FATE) is priced at $91.00 after the most recent trading session. At the very opening of the session, the stock price was $84.77 and reached a high price of $91.9003, prior to ...
- Peptilogics and Cerebras Systems Partner on AI Solutions to Advance Peptide Therapeuticson August 18, 2021 at 6:23 am
Cerebras Systems, the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics, a biotechnology platform company and an emerging leader in leveraging computation to design ...
via Bing News